MARKET INTRODUCTION
Pulmonary hypertension is a state of the body in which the blood pressure rises in the arteries. Pulmonary hypertension drugs belong to the class of anti-hypertensives drugs that are used specifically to treat pulmonary hypertension. In addition, this class of drugs treats life-threatening diseases such as ryanoids syndrome, arrhythmias, cephalagra, and angina.
MARKET DYNAMICS
The Pulmonary Hypertension Drug market is driving due to the increase in geriatric population, and prevalence of hypertension. Moreover, rising government initiatives with an objective of extensive research and development activities, and an increased awareness is driving the market growth.
MARKET SCOPE
The "Pulmonary Hypertension Drug Market Analysis to 2027" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of Pulmonary Hypertension Drug market with detailed market segmentation by product and application. The Pulmonary Hypertension Drug market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in Pulmonary Hypertension Drug market and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The Pulmonary Hypertension Drug market is segmented on the basis of product and application. Based on product, the market is segmented as Prostacyclin and Prostacyclin Analogs, Endothelin Receptor Antagonists, Phosphodiesterase-5 Inhibitors and Soluble Guanylate Cyclase Stimulators. Based on application , the market is segmented as Early-Stage Drug Candidates and Late-Stage Drug Candidates.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the Pulmonary Hypertension Drug market based on various segments. It also provides market size and forecast estimates from year 2017 to 2027 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The Pulmonary Hypertension Drug market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting Pulmonary Hypertension Drug market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the Pulmonary Hypertension Drug market in these regions.
MARKET PLAYERS
The report covers key developments in the Pulmonary Hypertension Drug market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from Pulmonary Hypertension Drug market are anticipated to have lucrative growth opportunities in the future with the rising demand for Pulmonary Hypertension Drug in the global market. Below mentioned is the list of few companies engaged in the Pulmonary Hypertension Drug market.
The report also includes the profiles of key players in Pulmonary Hypertension Drug market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- GlaxoSmithKline plc
- Novartis AG
- Merck & Co., Inc.
- Abbott Laboratories
- Boehringer Ingelheim GmbH
- AstraZeneca plc
- F. Hoffmann-La Roche AG
- Teva Pharmaceutical Industries Ltd.
- Vectura Group plc
- Pfizer Inc.
TABLE OF CONTENTS
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Pulmonary Hypertension Drug Market - By Product
1.3.2 Pulmonary Hypertension Drug Market - By Application
1.3.3 Pulmonary Hypertension Drug Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. PULMONARY HYPERTENSION DRUG MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PEST ANALYSIS
4.2.1 North America - Pest Analysis
4.2.2 Europe - Pest Analysis
4.2.3 Asia-Pacific - Pest Analysis
4.2.4 Middle East and Africa - Pest Analysis
4.2.5 South and Central America - Pest Analysis
4.3. EXPERT OPINIONS
5. PULMONARY HYPERTENSION DRUG MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. PULMONARY HYPERTENSION DRUG MARKET - GLOBAL MARKET ANALYSIS
6.1. PULMONARY HYPERTENSION DRUG - GLOBAL MARKET OVERVIEW
6.2. PULMONARY HYPERTENSION DRUG - GLOBAL MARKET AND FORECAST TO 2027
6.3. MARKET POSITIONING/MARKET SHARE
7. PULMONARY HYPERTENSION DRUG MARKET - REVENUE AND FORECASTS TO 2027 - PRODUCT
7.1. OVERVIEW
7.2. PRODUCT MARKET FORECASTS AND ANALYSIS
7.3. PROSTACYCLIN AND PROSTACYCLIN ANALOGS
7.3.1. Overview
7.3.2. Prostacyclin and Prostacyclin Analogs Market Forecast and Analysis
7.4. ENDOTHELIN RECEPTOR ANTAGONISTS
7.4.1. Overview
7.4.2. Endothelin Receptor Antagonists Market Forecast and Analysis
7.5. PHOSPHODIESTERASE-5 INHIBITORS
7.5.1. Overview
7.5.2. Phosphodiesterase-5 Inhibitors Market Forecast and Analysis
7.6. SOLUBLE GUANYLATE CYCLASE STIMULATOR
7.6.1. Overview
7.6.2. Soluble Guanylate Cyclase Stimulator Market Forecast and Analysis
8. PULMONARY HYPERTENSION DRUG MARKET - REVENUE AND FORECASTS TO 2027 - APPLICATION
8.1. OVERVIEW
8.2. APPLICATION MARKET FORECASTS AND ANALYSIS
8.3. EARLY-STAGE DRUG CANDIDATES
8.3.1. Overview
8.3.2. Early-Stage Drug Candidates Market Forecast and Analysis
8.4. LATE-STAGE DRUG CANDIDATES
8.4.1. Overview
8.4.2. Late-Stage Drug Candidates Market Forecast and Analysis
9. PULMONARY HYPERTENSION DRUG MARKET REVENUE AND FORECASTS TO 2027 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Pulmonary Hypertension Drug Market Overview
9.1.2 North America Pulmonary Hypertension Drug Market Forecasts and Analysis
9.1.3 North America Pulmonary Hypertension Drug Market Forecasts and Analysis - By Product
9.1.4 North America Pulmonary Hypertension Drug Market Forecasts and Analysis - By Application
9.1.5 North America Pulmonary Hypertension Drug Market Forecasts and Analysis - By Countries
9.1.5.1 United States Pulmonary Hypertension Drug Market
9.1.5.1.1 United States Pulmonary Hypertension Drug Market by Product
9.1.5.1.2 United States Pulmonary Hypertension Drug Market by Application
9.1.5.2 Canada Pulmonary Hypertension Drug Market
9.1.5.2.1 Canada Pulmonary Hypertension Drug Market by Product
9.1.5.2.2 Canada Pulmonary Hypertension Drug Market by Application
9.1.5.3 Mexico Pulmonary Hypertension Drug Market
9.1.5.3.1 Mexico Pulmonary Hypertension Drug Market by Product
9.1.5.3.2 Mexico Pulmonary Hypertension Drug Market by Application
9.2. EUROPE
9.2.1 Europe Pulmonary Hypertension Drug Market Overview
9.2.2 Europe Pulmonary Hypertension Drug Market Forecasts and Analysis
9.2.3 Europe Pulmonary Hypertension Drug Market Forecasts and Analysis - By Product
9.2.4 Europe Pulmonary Hypertension Drug Market Forecasts and Analysis - By Application
9.2.5 Europe Pulmonary Hypertension Drug Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Pulmonary Hypertension Drug Market
9.2.5.1.1 Germany Pulmonary Hypertension Drug Market by Product
9.2.5.1.2 Germany Pulmonary Hypertension Drug Market by Application
9.2.5.2 France Pulmonary Hypertension Drug Market
9.2.5.2.1 France Pulmonary Hypertension Drug Market by Product
9.2.5.2.2 France Pulmonary Hypertension Drug Market by Application
9.2.5.3 Italy Pulmonary Hypertension Drug Market
9.2.5.3.1 Italy Pulmonary Hypertension Drug Market by Product
9.2.5.3.2 Italy Pulmonary Hypertension Drug Market by Application
9.2.5.4 Spain Pulmonary Hypertension Drug Market
9.2.5.4.1 Spain Pulmonary Hypertension Drug Market by Product
9.2.5.4.2 Spain Pulmonary Hypertension Drug Market by Application
9.2.5.5 United Kingdom Pulmonary Hypertension Drug Market
9.2.5.5.1 United Kingdom Pulmonary Hypertension Drug Market by Product
9.2.5.5.2 United Kingdom Pulmonary Hypertension Drug Market by Application
9.2.5.6 Rest of Europe Pulmonary Hypertension Drug Market
9.2.5.6.1 Rest of Europe Pulmonary Hypertension Drug Market by Product
9.2.5.6.2 Rest of Europe Pulmonary Hypertension Drug Market by Application
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Pulmonary Hypertension Drug Market Overview
9.3.2 Asia-Pacific Pulmonary Hypertension Drug Market Forecasts and Analysis
9.3.3 Asia-Pacific Pulmonary Hypertension Drug Market Forecasts and Analysis - By Product
9.3.4 Asia-Pacific Pulmonary Hypertension Drug Market Forecasts and Analysis - By Application
9.3.5 Asia-Pacific Pulmonary Hypertension Drug Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Pulmonary Hypertension Drug Market
9.3.5.1.1 Australia Pulmonary Hypertension Drug Market by Product
9.3.5.1.2 Australia Pulmonary Hypertension Drug Market by Application
9.3.5.2 China Pulmonary Hypertension Drug Market
9.3.5.2.1 China Pulmonary Hypertension Drug Market by Product
9.3.5.2.2 China Pulmonary Hypertension Drug Market by Application
9.3.5.3 India Pulmonary Hypertension Drug Market
9.3.5.3.1 India Pulmonary Hypertension Drug Market by Product
9.3.5.3.2 India Pulmonary Hypertension Drug Market by Application
9.3.5.4 Japan Pulmonary Hypertension Drug Market
9.3.5.4.1 Japan Pulmonary Hypertension Drug Market by Product
9.3.5.4.2 Japan Pulmonary Hypertension Drug Market by Application
9.3.5.5 South Korea Pulmonary Hypertension Drug Market
9.3.5.5.1 South Korea Pulmonary Hypertension Drug Market by Product
9.3.5.5.2 South Korea Pulmonary Hypertension Drug Market by Application
9.3.5.6 Rest of Asia-Pacific Pulmonary Hypertension Drug Market
9.3.5.6.1 Rest of Asia-Pacific Pulmonary Hypertension Drug Market by Product
9.3.5.6.2 Rest of Asia-Pacific Pulmonary Hypertension Drug Market by Application
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Pulmonary Hypertension Drug Market Overview
9.4.2 Middle East and Africa Pulmonary Hypertension Drug Market Forecasts and Analysis
9.4.3 Middle East and Africa Pulmonary Hypertension Drug Market Forecasts and Analysis - By Product
9.4.4 Middle East and Africa Pulmonary Hypertension Drug Market Forecasts and Analysis - By Application
9.4.5 Middle East and Africa Pulmonary Hypertension Drug Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Pulmonary Hypertension Drug Market
9.4.5.1.1 South Africa Pulmonary Hypertension Drug Market by Product
9.4.5.1.2 South Africa Pulmonary Hypertension Drug Market by Application
9.4.5.2 Saudi Arabia Pulmonary Hypertension Drug Market
9.4.5.2.1 Saudi Arabia Pulmonary Hypertension Drug Market by Product
9.4.5.2.2 Saudi Arabia Pulmonary Hypertension Drug Market by Application
9.4.5.3 U.A.E Pulmonary Hypertension Drug Market
9.4.5.3.1 U.A.E Pulmonary Hypertension Drug Market by Product
9.4.5.3.2 U.A.E Pulmonary Hypertension Drug Market by Application
9.4.5.4 Rest of Middle East and Africa Pulmonary Hypertension Drug Market
9.4.5.4.1 Rest of Middle East and Africa Pulmonary Hypertension Drug Market by Product
9.4.5.4.2 Rest of Middle East and Africa Pulmonary Hypertension Drug Market by Application
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Pulmonary Hypertension Drug Market Overview
9.5.2 South and Central America Pulmonary Hypertension Drug Market Forecasts and Analysis
9.5.3 South and Central America Pulmonary Hypertension Drug Market Forecasts and Analysis - By Product
9.5.4 South and Central America Pulmonary Hypertension Drug Market Forecasts and Analysis - By Application
9.5.5 South and Central America Pulmonary Hypertension Drug Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Pulmonary Hypertension Drug Market
9.5.5.1.1 Brazil Pulmonary Hypertension Drug Market by Product
9.5.5.1.2 Brazil Pulmonary Hypertension Drug Market by Application
9.5.5.2 Argentina Pulmonary Hypertension Drug Market
9.5.5.2.1 Argentina Pulmonary Hypertension Drug Market by Product
9.5.5.2.2 Argentina Pulmonary Hypertension Drug Market by Application
9.5.5.3 Rest of South and Central America Pulmonary Hypertension Drug Market
9.5.5.3.1 Rest of South and Central America Pulmonary Hypertension Drug Market by Product
9.5.5.3.2 Rest of South and Central America Pulmonary Hypertension Drug Market by Application
10. IMPACT OF COVID-19 PANDEMIC ON GLOBAL PULMONARY HYPERTENSION DRUG MARKET
10.1 North America
10.2 Europe
10.3 Asia-Pacific
10.4 Middle East and Africa
10.5 South and Central America
11. INDUSTRY LANDSCAPE
11.1. MERGERS AND ACQUISITIONS
11.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
11.3. NEW PRODUCT LAUNCHES
11.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
12. PULMONARY HYPERTENSION DRUG MARKET, KEY COMPANY PROFILES
12.1. GLAXOSMITHKLINE PLC
12.1.1. Key Facts
12.1.2. Business Description
12.1.3. Products and Services
12.1.4. Financial Overview
12.1.5. SWOT Analysis
12.1.6. Key Developments
12.2. NOVARTIS AG
12.2.1. Key Facts
12.2.2. Business Description
12.2.3. Products and Services
12.2.4. Financial Overview
12.2.5. SWOT Analysis
12.2.6. Key Developments
12.3. MERCK AND CO., INC.
12.3.1. Key Facts
12.3.2. Business Description
12.3.3. Products and Services
12.3.4. Financial Overview
12.3.5. SWOT Analysis
12.3.6. Key Developments
12.4. ABBOTT LABORATORIES
12.4.1. Key Facts
12.4.2. Business Description
12.4.3. Products and Services
12.4.4. Financial Overview
12.4.5. SWOT Analysis
12.4.6. Key Developments
12.5. BOEHRINGER INGELHEIM GMBH
12.5.1. Key Facts
12.5.2. Business Description
12.5.3. Products and Services
12.5.4. Financial Overview
12.5.5. SWOT Analysis
12.5.6. Key Developments
12.6. ASTRAZENECA PLC
12.6.1. Key Facts
12.6.2. Business Description
12.6.3. Products and Services
12.6.4. Financial Overview
12.6.5. SWOT Analysis
12.6.6. Key Developments
12.7. F. HOFFMANN-LA ROCHE AG
12.7.1. Key Facts
12.7.2. Business Description
12.7.3. Products and Services
12.7.4. Financial Overview
12.7.5. SWOT Analysis
12.7.6. Key Developments
12.8. TEVA PHARMACEUTICAL INDUSTRIES LTD.
12.8.1. Key Facts
12.8.2. Business Description
12.8.3. Products and Services
12.8.4. Financial Overview
12.8.5. SWOT Analysis
12.8.6. Key Developments
12.9. VECTURA GROUP PLC
12.9.1. Key Facts
12.9.2. Business Description
12.9.3. Products and Services
12.9.4. Financial Overview
12.9.5. SWOT Analysis
12.9.6. Key Developments
12.10. PFIZER INC.
12.10.1. Key Facts
12.10.2. Business Description
12.10.3. Products and Services
12.10.4. Financial Overview
12.10.5. SWOT Analysis
12.10.6. Key Developments
13. APPENDIX
13.1. ABOUT THE INSIGHT PARTNERS
13.2. GLOSSARY OF TERMS
The List of Companies
1. GlaxoSmithKline plc
2. Novartis AG
3. Merck & Co., Inc.
4. Abbott Laboratories
5. Boehringer Ingelheim GmbH
6. AstraZeneca plc
7. F. Hoffmann-La Roche AG
8. Teva Pharmaceutical Industries Ltd.
9. Vectura Group plc
10. Pfizer Inc.